pI: 5.6874 |
Length (AA): 1013 |
MW (Da): 111612 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
510 | 1013 | 1z3i (X) | 124 | 668 | 30.00 | 0 | 1 | 0.762932 | 0.07 |
516 | 1009 | 1z6a (A) | 9 | 904 | 47.00 | 0 | 1 | 1.06126 | -0.53 |
523 | 980 | 3mwy (W) | 366 | 839 | 32.00 | 0 | 1 | 0.672722 | 0.6 |
532 | 977 | 5hzr (A) | 553 | 1057 | 33.00 | 0 | 1 | 0.668876 | 0.22 |
830 | 977 | 1t5i (A) | 270 | 406 | 19.00 | 0 | 0.91 | 0.359501 | -0.4 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Dormant phase. | murphy |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | Dormant phase. | hasan |
murphy | Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. |
hasan | Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. |
Ortholog group members (OG5_128804)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G54280 | TATA-binding protein-associated factor BTAF1 |
Brugia malayi | Bm1_36425 | SNF2 family N-terminal domain containing protein |
Candida albicans | CaO19.4502 | transcriptional accessory protein |
Candida albicans | CaO19.11978 | transcriptional accessory protein |
Caenorhabditis elegans | CELE_F15D4.1 | Protein BTF-1 |
Chlamydia trachomatis | CT_708 | SWF/SNF family helicase |
Dictyostelium discoideum | DDB_G0286219 | CHR group protein |
Drosophila melanogaster | Dmel_CG4261 | Helicase 89B |
Echinococcus granulosus | EgrG_000091200 | TATA binding protein associated factor 172 |
Echinococcus granulosus | EgrG_000091400 | helicase |
Echinococcus granulosus | EgrG_000090900 | TATA binding protein associated factor 172 |
Entamoeba histolytica | EHI_178810 | SNF2 family protein |
Echinococcus multilocularis | EmuJ_000090900 | TATA binding protein associated factor 172 |
Echinococcus multilocularis | EmuJ_000091200 | TATA binding protein associated factor 172 |
Echinococcus multilocularis | EmuJ_000091400 | helicase |
Homo sapiens | ENSG00000095564 | BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa |
Loa Loa (eye worm) | LOAG_02312 | SNF2 family domain-containing protein |
Mus musculus | ENSMUSG00000040565 | BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, (Mot1 homolog, S. cerevisiae) |
Mycobacterium tuberculosis | Rv2101 | Probable helicase HelZ |
Oryza sativa | 4328386 | Os02g0161300 |
Saccharomyces cerevisiae | YPL082C | Mot1p |
Schistosoma japonicum | Sjp_0018600 | TATA-binding protein-associated factor 172, putative |
Schistosoma japonicum | Sjp_0108530 | expressed protein |
Schistosoma japonicum | Sjp_0018590 | TATA-binding protein-associated factor 172, putative |
Schistosoma japonicum | Sjp_0018580 | ko:K01509 adenosinetriphosphatase [EC3.6.1.3], putative |
Schistosoma mansoni | Smp_158610.1 | helicase |
Schistosoma mansoni | Smp_158610.2 | helicase |
Schmidtea mediterranea | mk4.001776.02 | TATA-binding protein-associated factor 172 |
Trichomonas vaginalis | TVAG_142600 | lymphoid specific helicase, putative |
Trichomonas vaginalis | TVAG_142590 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_044640 | lymphoid specific helicase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu2134 this record | Mycobacterium tuberculosis | non-essential | nmpdr |
YPL082C | Saccharomyces cerevisiae | inviable | yeastgenome |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.2